CN103695448A - 一种透明质酸酶编码基因及其发酵生产和纯化方法 - Google Patents
一种透明质酸酶编码基因及其发酵生产和纯化方法 Download PDFInfo
- Publication number
- CN103695448A CN103695448A CN201410007408.1A CN201410007408A CN103695448A CN 103695448 A CN103695448 A CN 103695448A CN 201410007408 A CN201410007408 A CN 201410007408A CN 103695448 A CN103695448 A CN 103695448A
- Authority
- CN
- China
- Prior art keywords
- unidasa
- gene
- hyaluronidase
- nucleotide sequence
- leech
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010003272 Hyaluronate lyase Proteins 0.000 title claims abstract description 23
- 102000001974 Hyaluronidases Human genes 0.000 title claims abstract description 18
- 229960002773 hyaluronidase Drugs 0.000 title claims abstract description 18
- 238000000746 purification Methods 0.000 title claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 title claims description 36
- 238000000034 method Methods 0.000 title claims description 20
- 238000000855 fermentation Methods 0.000 title claims description 11
- 230000004151 fermentation Effects 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 230000000694 effects Effects 0.000 claims abstract description 33
- 239000002773 nucleotide Substances 0.000 claims abstract description 18
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 18
- 241000235058 Komagataella pastoris Species 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000012262 fermentative production Methods 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 239000007999 glycylglycine buffer Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- 241001506991 Komagataella phaffii GS115 Species 0.000 claims description 2
- 241000235648 Pichia Species 0.000 claims description 2
- 239000012531 culture fluid Substances 0.000 claims description 2
- 230000008034 disappearance Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000011218 seed culture Methods 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 241000545744 Hirudinea Species 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000006798 recombination Effects 0.000 abstract description 4
- 238000005215 recombination Methods 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002270 dispersing agent Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 description 32
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 30
- 229960003160 hyaluronic acid Drugs 0.000 description 30
- 239000007788 liquid Substances 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 5
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940059329 chondroitin sulfate Drugs 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 238000004848 nephelometry Methods 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101100377797 Arabidopsis thaliana ABCC1 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 101150025806 Est1 gene Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 150000003538 tetroses Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000006098 transglycosylation Effects 0.000 description 2
- 238000005918 transglycosylation reaction Methods 0.000 description 2
- AURFVNDXGLQSNN-UHFFFAOYSA-K trisodium 2-hydroxypropane-1,2,3-tricarboxylic acid phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O AURFVNDXGLQSNN-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- AALORNCJXUQNQW-FNGWHDOKSA-N (2r,3r,4s)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2h-pyran-6-carboxylic acid Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@H](O)[C@H](O)CO)O[C@@H]1OC(C(O)=O)=C[C@H](O)[C@H]1O AALORNCJXUQNQW-FNGWHDOKSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Images
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410007408.1A CN103695448B (zh) | 2013-07-29 | 2014-01-08 | 一种透明质酸酶编码基因及其发酵生产和纯化方法 |
US14/251,579 US9279111B2 (en) | 2013-07-29 | 2014-04-12 | Leech hyaluronidase and its application |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310323064 | 2013-07-29 | ||
CN2013103230640 | 2013-07-29 | ||
CN201310323064.0 | 2013-07-29 | ||
CN201410007408.1A CN103695448B (zh) | 2013-07-29 | 2014-01-08 | 一种透明质酸酶编码基因及其发酵生产和纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103695448A true CN103695448A (zh) | 2014-04-02 |
CN103695448B CN103695448B (zh) | 2016-08-17 |
Family
ID=50357112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410007408.1A Active CN103695448B (zh) | 2013-07-29 | 2014-01-08 | 一种透明质酸酶编码基因及其发酵生产和纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103695448B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104212732A (zh) * | 2014-09-12 | 2014-12-17 | 江南大学 | 一种产透明质酸的重组毕赤酵母及其构建方法 |
CN104232804B (zh) * | 2014-10-08 | 2016-03-23 | 江南大学 | 一种梯度变温诱导提高透明质酸酶表达量的方法 |
CN105524977A (zh) * | 2015-12-30 | 2016-04-27 | 广州医科大学 | 一种快速测定透明质酸酶活性的方法 |
CN113876623A (zh) * | 2021-09-24 | 2022-01-04 | 华熙生物科技股份有限公司 | 一种透明质酸寡糖组合物在抗皮肤衰老、促进胶原蛋白生成中的用途 |
WO2022183541A1 (zh) * | 2021-03-05 | 2022-09-09 | 华熙生物科技股份有限公司 | 一种密码子优化的透明质酸水解酶基因及其表达 |
WO2023040952A1 (zh) * | 2021-09-17 | 2023-03-23 | 华熙生物科技股份有限公司 | 一种透明质酸寡糖组合物及其制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355850A (zh) * | 1999-06-12 | 2002-06-26 | 默克专利股份有限公司 | 来源于马尼拉水蛭的透明质酸酶,分离、纯化和重组生产方法 |
CN102911886A (zh) * | 2011-08-02 | 2013-02-06 | 山东省生物药物研究院 | 利用毕赤酵母基因调控直接发酵制备一种抗肿瘤药物复合物的方法 |
CN103436508A (zh) * | 2013-08-15 | 2013-12-11 | 江南大学 | 一种高效重组表达透明质酸酶的方法 |
CN103484513A (zh) * | 2013-10-22 | 2014-01-01 | 江南大学 | 一种酶法制备小分子寡聚透明质酸的方法 |
-
2014
- 2014-01-08 CN CN201410007408.1A patent/CN103695448B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355850A (zh) * | 1999-06-12 | 2002-06-26 | 默克专利股份有限公司 | 来源于马尼拉水蛭的透明质酸酶,分离、纯化和重组生产方法 |
US7049124B1 (en) * | 1999-06-12 | 2006-05-23 | Merck Patent Gmbh | Hyaluronidase from the Hirudinaria manillensis isolation, purification and recombinant method of production |
CN102911886A (zh) * | 2011-08-02 | 2013-02-06 | 山东省生物药物研究院 | 利用毕赤酵母基因调控直接发酵制备一种抗肿瘤药物复合物的方法 |
CN103436508A (zh) * | 2013-08-15 | 2013-12-11 | 江南大学 | 一种高效重组表达透明质酸酶的方法 |
CN103484513A (zh) * | 2013-10-22 | 2014-01-01 | 江南大学 | 一种酶法制备小分子寡聚透明质酸的方法 |
Non-Patent Citations (2)
Title |
---|
KORDOWICZ,M.等: "ABH83946", 《GENBANK》, 11 August 2006 (2006-08-11), pages 1 * |
王晓玉: "重组人透明质酸酶PH-20在毕赤酵母中的表达,发酵条件优化及性质研究", 《中国优秀硕士学位论文全文数据库 基础科学辑》, no. 4, 15 April 2012 (2012-04-15), pages 006 - 143 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104212732A (zh) * | 2014-09-12 | 2014-12-17 | 江南大学 | 一种产透明质酸的重组毕赤酵母及其构建方法 |
CN104232804B (zh) * | 2014-10-08 | 2016-03-23 | 江南大学 | 一种梯度变温诱导提高透明质酸酶表达量的方法 |
CN105524977A (zh) * | 2015-12-30 | 2016-04-27 | 广州医科大学 | 一种快速测定透明质酸酶活性的方法 |
WO2022183541A1 (zh) * | 2021-03-05 | 2022-09-09 | 华熙生物科技股份有限公司 | 一种密码子优化的透明质酸水解酶基因及其表达 |
WO2023040952A1 (zh) * | 2021-09-17 | 2023-03-23 | 华熙生物科技股份有限公司 | 一种透明质酸寡糖组合物及其制备方法和用途 |
CN113876623A (zh) * | 2021-09-24 | 2022-01-04 | 华熙生物科技股份有限公司 | 一种透明质酸寡糖组合物在抗皮肤衰老、促进胶原蛋白生成中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103695448B (zh) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103695448A (zh) | 一种透明质酸酶编码基因及其发酵生产和纯化方法 | |
CN103614352B (zh) | 一种高效重组表达透明质酸酶的方法 | |
CN102964461B (zh) | 一种提高石斛生物活性多糖溶出率的生物酶辅助提取方法 | |
CN109912700B (zh) | 一种利用β-1,6葡聚糖酶联产酵母葡聚糖、甘露糖蛋白和酵母提取物的方法 | |
CN104278005A (zh) | 一种表达透明质酸酶的重组枯草芽孢杆菌 | |
CN102199583B (zh) | 几丁质酶ChiCD3及其编码基因和应用 | |
CN104263707A (zh) | 一种提高毕赤酵母重组表达透明质酸酶的方法 | |
CN114350639B (zh) | 一种密码子优化的透明质酸水解酶基因及其表达 | |
CN103484513A (zh) | 一种酶法制备小分子寡聚透明质酸的方法 | |
CN103146592B (zh) | 一种转化人参皂苷Rb1生成Rd的酵母菌及其应用 | |
WO2015180362A1 (zh) | 一种嗜温耐乙醇β-葡萄糖苷酶及其编码基因和应用 | |
CN102787108A (zh) | 来源于里氏木霉的一个蛋白质及其基因的用途 | |
CN101654680B (zh) | 产β-葡萄糖苷酶的重组菌的构建方法 | |
CN107312765A (zh) | 一种难以降解cs‑e的糖胺聚糖裂解酶及其编码基因与应用 | |
CN101818161A (zh) | 一种纤维二糖酶基因 | |
CN104178539A (zh) | 一种规模化制备特定分子量小分子透明质酸的方法 | |
CN103923899A (zh) | 一种糖胺聚糖裂解酶及其编码基因与应用 | |
CN112920285B (zh) | 一种米糠多糖的制备方法及其应用 | |
CN112266907B (zh) | 齐整小核菌内源小核菌胶水解酶及应用 | |
WO2009022221A2 (en) | Composition and method to stimulate growth and defense against pathogens in plants | |
CN103194459A (zh) | 高生物量和/或高叶黄素产量转基因小球藻及其制备方法 | |
CN113862240B (zh) | 一种密码子优化的糖苷酶swmu-f2-2及其制备方法与应用 | |
CN103255118A (zh) | 一种β-甘露聚糖酶、编码基因及其生产菌和应用 | |
CN106554951A (zh) | 重组鹰嘴豆孢克鲁维酵母cbs4857外切菊粉酶及编码基因与表达和应用 | |
CN103667212A (zh) | 一种糖化酶及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Jian Inventor after: Du Guocheng Inventor after: Kang Zhen Inventor after: Li Jianghua Inventor after: Jin Peng Inventor before: Chen Jian Inventor before: Du Guocheng Inventor before: Kang Zhen Inventor before: Jin Peng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN JIAN DU GUOCHENG KANG ZHEN JIN PENG TO: CHEN JIAN DU GUOCHENG KANG ZHEN LI JIANGHUA JIN PENG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140402 Assignee: NANJING HANXIN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Assignor: Jiangnan University Contract record no.: X2020320000330 Denomination of invention: A hyaluronidase coding gene and its fermentation production and purification method Granted publication date: 20160817 License type: Common License Record date: 20201212 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140402 Assignee: Nanjing letao Biotechnology Co.,Ltd. Assignor: Jiangnan University Contract record no.: X2023980034160 Denomination of invention: A hyaluronidase coding gene and its fermentation production and purification method Granted publication date: 20160817 License type: Common License Record date: 20230328 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140402 Assignee: Shuiyang Cosmetics Manufacturing Co.,Ltd. Assignor: Jiangnan University Contract record no.: X2024980001575 Denomination of invention: A Hyaluronidase Encoding Gene and Its Fermentation Production and Purification Method Granted publication date: 20160817 License type: Common License Record date: 20240130 |